@T_M_Alshammari Important questions still under discussion; a European perspective was published here https://t.co/EmEmUlbvBE
RT @EdurneGamarra: Hot topic 💥 at #EAHP2019: Interchangeability of Biosimilars https://t.co/eZLRCvTVlF
RT @EdurneGamarra: Hot topic 💥 at #EAHP2019: Interchangeability of Biosimilars https://t.co/eZLRCvTVlF
RT @EdurneGamarra: Hot topic 💥 at #EAHP2019: Interchangeability of Biosimilars https://t.co/eZLRCvTVlF
RT @EdurneGamarra: Hot topic 💥 at #EAHP2019: Interchangeability of Biosimilars https://t.co/eZLRCvTVlF
Hot topic 💥 at #EAHP2019: Interchangeability of Biosimilars https://t.co/eZLRCvTVlF
RT @AnnemarieVtW: Interchangeability of #Biosimilars: A European Perspective | SpringerLink https://t.co/BulPeDMtsQ
RT @claudiavaca5: "experience with biosimilars has shown that even complex biotechnology-derived proteins can be copied successfully" https…
RT @claudiavaca5: "experience with biosimilars has shown that even complex biotechnology-derived proteins can be copied successfully" https…
RT @claudiavaca5: "Switch between comparable versions of the same active substance... is not expected to trigger or enhance immunogenicity"…
RT @claudiavaca5: "experience with biosimilars has shown that even complex biotechnology-derived proteins can be copied successfully" https…
RT @claudiavaca5: "experience with biosimilars has shown that even complex biotechnology-derived proteins can be copied successfully" https…
"Switch between comparable versions of the same active substance... is not expected to trigger or enhance immunogenicity" @agaviriau https://t.co/GN2vmBNMCW
"experience with biosimilars has shown that even complex biotechnology-derived proteins can be copied successfully" https://t.co/GN2vmBNMCW
RT @Tr0ttaFra: Biosimilars licensed in the EU are interchangeable. https://t.co/peBECO3xPN https://t.co/pqoOXr8jgE
RT @Tr0ttaFra: Biosimilars licensed in the EU are interchangeable. https://t.co/peBECO3xPN https://t.co/pqoOXr8jgE
RT @Tr0ttaFra: Biosimilars licensed in the EU are interchangeable. https://t.co/peBECO3xPN https://t.co/pqoOXr8jgE
RT @Tr0ttaFra: Biosimilars licensed in the EU are interchangeable. https://t.co/peBECO3xPN https://t.co/pqoOXr8jgE
Biosimilars licensed in the EU are interchangeable. https://t.co/peBECO3xPN https://t.co/pqoOXr8jgE
RT @medisien: Switch between biosimilar versions of a biologic is not expected to trigger immunogenicity.https://t.co/i7JkDTrJWm
RT @medisien: Our conclusion is that biosimilars licensed in the EU are interchangeable.✋biologic monopoly abuse https://t.co/i7JkDTrJWm
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
RT @FKuriBrena: Intercambiabilidad de #biosimilares. https://t.co/WK5nBI4wtP
Our conclusion is that biosimilars licensed in the EU are interchangeable.✋biologic monopoly abuse https://t.co/i7JkDTrJWm
Switch between biosimilar versions of a biologic is not expected to trigger immunogenicity.https://t.co/i7JkDTrJWm
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
Intercambiabilidad de #biosimilares. https://t.co/WK5nBI4wtP
No reticence here: "Our conclusion is that biosimilars licensed in the EU are interchangeable." https://t.co/E3NsKJWhee
RT @biosimilarz: EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
EMA's (in)formal position on #biosimilar interchangeability (or is that switching); https://t.co/VzvxU5RK2T
Interchangeability of Biosimilars: A European Perspective https://t.co/j1E2YZbyBg #pharma #STEM